Dan O’Day drives Gilead's mission to end HIV worldwide, pioneering treatments like lenacapavir and championing global health ...
Gilead (GILD) reported positive results from a pivotal Phase 3 study of its twice-yearly HIV prevention treatment lenacapavir ...
An update from the PURPOSE 2 trial focused on adherence and pharmacokinetics data for lenacapavir, used to prevent HIV.
Sciences presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial, which is studying ...
Citi initiated coverage of Gilead (GILD) with a Buy rating and $125 price target The firm says that despite the stock’s near-term ...
Insights speaks directly to the people with an inside track on the big issues. Here, Dan Glass demands pharmaceutical company ...
Gilead’s layoffs include 72 employees at its Seattle location, which will close. Kite will shut down its Philadelphia ...
Analysts note that Gilead's HIV portfolio remains strong, with the potential for further expansion through new developments such as lenacapavir, a long-acting pre-exposure prophylaxis (PrEP ...
The scope of Gilead Sciences' recent round of layoffs is coming into clearer view with the revelation that the company is ...
Analysts note that Gilead's HIV portfolio remains strong, with the potential for further expansion through new developments such as lenacapavir, a long-acting pre-exposure prophylaxis (PrEP) treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback